Who makes JS7 plasmid DNA and MVA62B vaccine?

JS7 plasmid DNA and MVA62B vaccine is developed by GeoVax, Inc..

What development phase is JS7 plasmid DNA and MVA62B vaccine in?

JS7 plasmid DNA and MVA62B vaccine is in Phase 1.

Last reviewed 2026-05-14 · How we verify

JS7 plasmid DNA and MVA62B vaccine

GeoVax, Inc. · Phase 1 active Biologic

At a glance

Generic name	JS7 plasmid DNA and MVA62B vaccine
Also known as	pGA2/JS7 and MVA/HIV62B vaccine
Sponsor	GeoVax, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JS7 plasmid DNA and MVA62B vaccine CI brief — competitive landscape report
JS7 plasmid DNA and MVA62B vaccine updates RSS · CI watch RSS
GeoVax, Inc. portfolio CI